Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neogenomics Inc (NEO)

Neogenomics Inc (NEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Why NeoGenomics (NEO) Shares Are Falling Today

Why NeoGenomics (NEO) Shares Are Falling Today

NEO : 9.89 (-1.20%)
NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences:...

NEO : 9.89 (-1.20%)
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook

NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook

NEO : 9.89 (-1.20%)
NeoGenomics’s (NASDAQ:NEO) Q4 CY2025 Sales Beat Estimates

NeoGenomics’s (NASDAQ:NEO) Q4 CY2025 Sales Beat Estimates

NEO : 9.89 (-1.20%)
NeoGenomics: Q4 Earnings Snapshot

NeoGenomics: Q4 Earnings Snapshot

NEO : 9.89 (-1.20%)
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

Full-year revenue increased 10% to $727 million; Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition; Successfully resolved RaDaR ST patent...

NEO : 9.89 (-1.20%)
NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look For

NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look For

NEO : 9.89 (-1.20%)
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection

New integrated testing approach provides potential to deliver earlier biomarker insights, reduce diagnostic uncertainty in complex cancer cases, and enable confident clinical decisions

NEO : 9.89 (-1.20%)
1 Stock Under $50 Worth Your Attention and 2 We Brush Off

1 Stock Under $50 Worth Your Attention and 2 We Brush Off

CHWY : 26.45 (+2.28%)
ALHC : 20.60 (-1.15%)
NEO : 9.89 (-1.20%)
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial...

NEO : 9.89 (-1.20%)

Barchart Exclusives

Record IPOs Are Back: Why Retail Investors May Be Walking Into A Trap
When IPO calendars fill and enthusiasm peaks, remember this: an IPO is a liquidity event for insiders, not a gift to retail, and history shows late buyers usually fund the exit. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar